Free PANCE Practice Questions

Hematology PANCE practice questions

10 free, board-style Hematology questions for the PANCE, each with the correct answer and a complete explanation. No email, no account required.

Hematology is 5% of the PANCE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.

Question 1HematologyMedium
A 65-year-old man on a heparin infusion for an acute deep vein thrombosis has a platelet count fall from 240,000 to 72,000/microL on hospital day 5 and develops a new cool, pulseless right leg from acute arterial thrombosis. A 4T score is high, and a heparin-PF4 antibody assay is sent. Which of the following is the most appropriate next step in management?
  • AStart argatroban
  • BTransfuse platelets
  • CContinue heparin
  • DSwitch to enoxaparin
  • EStart warfarin
Reveal answer & full explanation
Correct answer: A — Start argatroban
  • AStart argatroban✓
  • BTransfuse platelets
  • CContinue heparin
  • DSwitch to enoxaparin
  • EStart warfarin

Why Start argatroban is correct

  • This is heparin-induced thrombocytopenia (HIT) type II, an immune reaction in which antibodies to heparin-platelet factor 4 complexes activate platelets, causing a roughly 50% platelet drop 5 to 10 days after heparin exposure with paradoxical arterial and venous thrombosis.
  • Management requires immediately stopping all heparin exposure (including LMWH and line flushes) and starting a non-heparin anticoagulant.
  • Argatroban, a direct thrombin inhibitor, is the appropriate agent and, because it is cleared by the liver, is preferred in renal impairment.

Why the others are wrong

  • Continue heparin — Perpetuates antibody-mediated platelet activation and worsens thrombosis.
  • Start warfarin — Must not be started while the patient is acutely thrombocytopenic, because protein C depletion can precipitate warfarin-induced skin necrosis and venous limb gangrene; warfarin is added only after platelets recover and with overlap on a non-heparin agent.
  • Switch to enoxaparin — Enoxaparin is a low-molecular-weight heparin and cross-reacts with HIT antibodies, so switching to it does not remove the offending exposure and is contraindicated.
  • Transfuse platelets — a falling platelet count can prompt platelet replacement, but bleeding is uncommon in HIT and transfused platelets may add to antibody-mediated platelet activation and thrombosis; transfusion is reserved for active bleeding or a high-risk invasive procedure, and the count recovers once heparin is stopped and a non-heparin anticoagulant is started.

Additional high-yield points

  • Platelet transfusion is also avoided in HIT as it can fuel further thrombosis.
Question 2HematologyMedium
A 65-year-old man presents with fatigue and exertional dyspnea. Labs show Hgb 8.4 g/dL, MCV 72 fL, ferritin 8 ng/mL, and elevated total iron-binding capacity. He reports no overt bleeding and takes no NSAIDs. Which of the following is the most important underlying cause to exclude?
  • ADietary iron deficiency
  • BMalabsorption from celiac disease
  • CBleeding colonic angiodysplasia
  • DBleeding peptic ulcer disease
  • EOccult gastrointestinal malignancy
Reveal answer & full explanation
Correct answer: E — Occult gastrointestinal malignancy
  • ADietary iron deficiency
  • BMalabsorption from celiac disease
  • CBleeding colonic angiodysplasia
  • DBleeding peptic ulcer disease
  • EOccult gastrointestinal malignancy✓

Why Occult gastrointestinal malignancy is correct

  • Iron deficiency anemia (low MCV, low ferritin, high TIBC) demands a cause-directed workup.
  • In men and postmenopausal women, occult gastrointestinal blood loss must be investigated with endoscopy/colonoscopy, and GI malignancy is the most important cause to exclude.
  • Low ferritin is the most sensitive indicator of iron deficiency, and a high TIBC supports the diagnosis.

Why the others are wrong

  • Dietary iron deficiency — Dietary deficiency is uncommon in adults eating a Western diet.
  • Bleeding peptic ulcer disease — H. pylori or idiopathic ulcers can cause occult upper GI blood loss and are evaluated on the same endoscopic workup, but in a 65-year-old man without NSAID use the cause that must not be missed is colorectal or gastric cancer, so malignancy is the most important to exclude.
  • Malabsorption from celiac disease — Can cause iron deficiency and should be considered, but is far less likely than occult GI malignancy in an older man and would usually have other malabsorptive features.
  • Bleeding colonic angiodysplasia — vascular ectasias are a common source of occult GI blood loss in older adults and are seen on the same endoscopic evaluation, but they are benign and should be accepted as the cause only after malignancy has been excluded, because colorectal or gastric cancer is the must-not-miss lesion in a 65-year-old man.
Question 3HematologyMedium
A 54-year-old man presents with fatigue, early satiety, and a 10-pound weight loss over three months. On exam, the spleen is palpable 8 cm below the left costal margin. Laboratory studies show WBC 142,000/microL with a left-shifted differential including myelocytes, metamyelocytes, basophilia, and eosinophilia, hemoglobin 11.2 g/dL, and platelets 480,000/microL. Leukocyte alkaline phosphatase score is low. Which of the following tests will most likely confirm the diagnosis?
  • ASerum protein electrophoresis
  • BFlow cytometry for CD5/CD19 coexpression
  • CBCR-ABL1 fusion testing
  • DPML-RARA fusion testing
  • EJAK2 V617F mutation testing
Reveal answer & full explanation
Correct answer: C — BCR-ABL1 fusion testing
  • ASerum protein electrophoresis
  • BFlow cytometry for CD5/CD19 coexpression
  • CBCR-ABL1 fusion testing✓
  • DPML-RARA fusion testing
  • EJAK2 V617F mutation testing

Why BCR-ABL1 fusion testing is correct

  • This middle-aged patient has the classic chronic myelogenous leukemia (CML) presentation: massive splenomegaly, marked leukocytosis with the full spectrum of granulocyte precursors, basophilia, and eosinophilia.
  • A low leukocyte alkaline phosphatase score separates CML from a leukemoid reaction and from other myeloproliferative neoplasms, which typically show a normal or high score.
  • CML is defined by the t(9;22) Philadelphia chromosome, which fuses BCR and ABL1; detecting the BCR-ABL1 fusion by FISH, RT-PCR, or cytogenetics confirms the diagnosis and identifies the target for tyrosine kinase inhibitor therapy.

Why the others are wrong

  • JAK2 V617F mutation testing — JAK2 V617F is the molecular hallmark of polycythemia vera and is also seen in essential thrombocythemia and primary myelofibrosis - conditions that typically lack the marked left-shifted granulocytosis and basophilia of CML (confused-with another myeloproliferative neoplasm).
  • Flow cytometry for CD5/CD19 coexpression — Coexpression of CD5 and CD19 identifies chronic lymphocytic leukemia, which presents with lymphocytosis and smudge cells, not a left-shifted myeloid series (buzzword-matching 'leukemia' to the lymphoid lineage).
  • Serum protein electrophoresis — Serum protein electrophoresis detects monoclonal gammopathies such as multiple myeloma or MGUS and does not address a myeloid leukocytosis (premature closure on an unrelated paraproteinemia).
  • PML-RARA fusion testing — the t(15;17) fusion is also a hallmark myeloid leukemia translocation, but it defines acute promyelocytic leukemia, which typically presents with pancytopenia, abnormal promyelocytes with Auer rods, and DIC rather than a chronic course with massive splenomegaly and a full spectrum of maturing granulocytes with basophilia (confused-with another leukemia translocation).
Question 4HematologyMedium
A 4-year-old boy of Mediterranean descent is brought to clinic for evaluation of pallor and poor growth. His mother reports he has been chronically fatigued and has fallen below the 5th percentile for height and weight. On exam, he has frontal bossing, maxillary prominence, and a palpable spleen 4 cm below the costal margin. Labs show Hgb 6.2 g/dL, MCV 58 fL, and numerous target cells and nucleated RBCs on smear. Hemoglobin electrophoresis shows HbF 85%, HbA2 6%, and HbA <2%. Which of the following is the most appropriate long-term management?
  • AChronic transfusion with iron chelation
  • BEarly splenectomy at diagnosis
  • COral ferrous sulfate supplementation
  • DHydroxyurea monotherapy
  • ETransfusion only for symptomatic anemia
Reveal answer & full explanation
Correct answer: A — Chronic transfusion with iron chelation
  • AChronic transfusion with iron chelation✓
  • BEarly splenectomy at diagnosis
  • COral ferrous sulfate supplementation
  • DHydroxyurea monotherapy
  • ETransfusion only for symptomatic anemia

Why Chronic transfusion with iron chelation is correct

  • This child has beta thalassemia major (Cooley anemia), caused by homozygous beta-globin gene mutations that abolish beta-chain production
  • Ineffective erythropoiesis drives severe microcytic anemia, extramedullary hematopoiesis (frontal bossing, maxillary prominence, hepatosplenomegaly), and growth failure
  • Hemoglobin electrophoresis classically shows markedly elevated HbF (85%), elevated HbA2, and absent or near-absent HbA (<2%)
  • Standard of care is lifelong chronic transfusion therapy targeting a pre-transfusion Hgb around 9-10.5 g/dL to suppress ineffective erythropoiesis
  • Iron chelation (deferasirox, deferoxamine, or deferiprone) is combined to prevent transfusion-related hemosiderosis
  • Allogeneic hematopoietic stem cell transplant is curative in eligible patients

Why the others are wrong

  • Oral ferrous sulfate supplementation — treats iron deficiency, which is not the underlying problem here; risks compounding iron overload
  • Hydroxyurea monotherapy — increases HbF and is the mainstay in sickle cell disease and useful in some beta thalassemia intermedia patients, but does not replace transfusion in transfusion-dependent thalassemia major
  • Early splenectomy at diagnosis — reserved for patients with hypersplenism causing rising transfusion requirements; delayed until at least age 5 due to overwhelming post-splenectomy infection risk
  • Transfusion only for symptomatic anemia — transfusion is the right therapy, which is why it tempts, but transfusing only when symptoms appear lets the Hgb sit low between transfusions, so ineffective erythropoiesis keeps expanding the marrow and spleen and the growth failure continues; thalassemia major needs a regular schedule that holds the pre-transfusion Hgb around 9-10.5 g/dL, paired with iron chelation
Question 5HematologyMedium
A 68-year-old man presents with fatigue. Physical examination reveals diffuse, painless lymphadenopathy. A complete blood count shows a WBC of 85,000/µL with a predominance of mature small lymphocytes, and the peripheral smear shows numerous smudge cells. Flow cytometry of the peripheral blood demonstrates a clonal B-cell population that is CD5-positive, CD19-positive, and CD23-positive. Which of the following is the most likely diagnosis?
  • AChronic lymphocytic leukemia
  • BHairy cell leukemia
  • CAcute lymphoblastic leukemia
  • DMantle cell lymphoma
  • EFollicular lymphoma
Reveal answer & full explanation
Correct answer: A — Chronic lymphocytic leukemia
  • AChronic lymphocytic leukemia✓
  • BHairy cell leukemia
  • CAcute lymphoblastic leukemia
  • DMantle cell lymphoma
  • EFollicular lymphoma

Why Chronic lymphocytic leukemia is correct

  • Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and typically presents after age 60 with fatigue and painless lymphadenopathy
  • The peripheral smear shows mature small lymphocytes with smudge cells, fragile leukemic cells that rupture during slide preparation
  • The clone carries the characteristic immunophenotype CD5+, CD19+, and CD23+, confirming a clonal mature B-cell process
  • Marked lymphocytosis (WBC 85,000/µL) of mature-appearing lymphocytes supports CLL over an acute or aggressive process

Why the others are wrong

  • Hairy cell leukemia — typically causes pancytopenia and massive splenomegaly with fine cytoplasmic projections and is CD23-negative; the marked lymphocytosis and CD23 positivity argue against it (confused-with another indolent B-cell neoplasm)
  • Mantle cell lymphoma — also CD5-positive but is characteristically CD23-NEGATIVE and more aggressive; the CD23 positivity here defeats it (buzzword-matching CD5 without integrating CD23)
  • Acute lymphoblastic leukemia — presents with circulating blasts rather than mature lymphocytes and is far more common in children; the mature lymphocyte morphology and smudge cells rule it out (anchoring on the high WBC)
  • Follicular lymphoma — the most common indolent non-Hodgkin lymphoma also causes painless, diffuse lymphadenopathy in older adults, but its clone is typically CD10-positive and CD5-negative with t(14;18) BCL2 overexpression, and it does not usually present with a marked lymphocytosis of mature lymphocytes and smudge cells (anchoring on painless adenopathy in an older adult)
Question 6HematologyMedium
A 35-year-old woman presents with easy bruising and petechiae over both lower extremities. She is otherwise well and takes no medications. Physical examination shows no splenomegaly or lymphadenopathy. A complete blood count shows isolated thrombocytopenia with a platelet count of 14,000/µL and large platelets on the smear; the hemoglobin and white blood cell count are normal. Which of the following is the most likely diagnosis?
  • AThrombotic thrombocytopenic purpura (TTP)
  • BEDTA-dependent pseudothrombocytopenia
  • CMyelodysplastic syndrome (MDS)
  • DDisseminated intravascular coagulation (DIC)
  • EImmune thrombocytopenia (ITP)
Reveal answer & full explanation
Correct answer: E — Immune thrombocytopenia (ITP)
  • AThrombotic thrombocytopenic purpura (TTP)
  • BEDTA-dependent pseudothrombocytopenia
  • CMyelodysplastic syndrome (MDS)
  • DDisseminated intravascular coagulation (DIC)
  • EImmune thrombocytopenia (ITP)✓

Why Immune thrombocytopenia (ITP) is correct

  • ITP produces isolated thrombocytopenia with large (young) platelets on the smear and an otherwise normal CBC
  • It is a diagnosis of exclusion; secondary causes (HIV, hepatitis C, drug-induced, systemic lupus erythematosus) must be ruled out
  • The absence of anemia, leukopenia, splenomegaly, and microangiopathic features points to immune-mediated peripheral platelet destruction
  • Initial treatment is corticosteroids (prednisone 1–2 mg/kg/day), with IVIG when a rapid platelet rise is needed for active bleeding or surgery

Why the others are wrong

  • Thrombotic thrombocytopenic purpura (TTP) — requires microangiopathic hemolytic anemia with schistocytes, often with fever, neurologic changes, and renal dysfunction; the isolated thrombocytopenia without hemolysis excludes it (confused-with another cause of thrombocytopenia)
  • Myelodysplastic syndrome (MDS) — can occasionally present as isolated thrombocytopenia, but it is a clonal marrow disorder of older adults (median age about 70) that typically shows macrocytosis, dysplastic cells, or additional cytopenias; in a healthy 35-year-old with an otherwise normal CBC and no dysplastic features, peripheral immune destruction is far more likely (premature closure on the low platelet count)
  • Disseminated intravascular coagulation (DIC) — occurs in acutely ill patients and produces a consumptive coagulopathy with prolonged PT/INR and low fibrinogen; this well patient with an otherwise normal CBC does not fit (buzzword-matching low platelets)
  • EDTA-dependent pseudothrombocytopenia — a common laboratory artifact in which EDTA induces platelet clumping, so it tempts when an otherwise well patient has an isolated low count; however, it causes no bleeding and the smear shows platelet clumps, whereas this patient has petechiae and bruising with large platelets, indicating true thrombocytopenia (anchoring on the isolated lab abnormality)
Question 7HematologyMedium
A 72-year-old man presents with several weeks of worsening lower back pain. Laboratory studies show hypercalcemia and a monoclonal (M) spike on serum protein electrophoresis. Urine studies reveal Bence-Jones (monoclonal light-chain) proteinuria, and a bone marrow biopsy shows 30% clonal plasma cells. Which of the following is the most likely diagnosis?
  • ASmoldering multiple myeloma
  • BMultiple myeloma
  • CMonoclonal gammopathy of undetermined significance
  • DSolitary plasmacytoma
  • EWaldenström's macroglobulinemia
Reveal answer & full explanation
Correct answer: B — Multiple myeloma
  • ASmoldering multiple myeloma
  • BMultiple myeloma✓
  • CMonoclonal gammopathy of undetermined significance
  • DSolitary plasmacytoma
  • EWaldenström's macroglobulinemia

Why Multiple myeloma is correct

  • Multiple myeloma is defined by clonal bone marrow plasma cells (≥10%) plus end-organ damage from the CRAB criteria: hyperCalcemia, Renal insufficiency, Anemia, and lytic Bone lesions
  • This patient has 30% marrow plasma cells, an M-spike on serum protein electrophoresis, hypercalcemia, bone pain, and Bence-Jones (light-chain) proteinuria — diagnostic of symptomatic myeloma
  • The combination of a monoclonal protein with myeloma-defining end-organ damage distinguishes it from premalignant plasma cell disorders

Why the others are wrong

  • Monoclonal gammopathy of undetermined significance — requires <10% marrow plasma cells, an M-protein <3 g/dL, and NO end-organ damage; the 30% plasma cells and hypercalcemia exclude it (premature closure on the M-spike alone)
  • Solitary plasmacytoma — is a single localized plasma cell mass with a normal marrow and no CRAB features; the diffuse marrow involvement defeats it (confused-with localized plasma cell disease)
  • Waldenström's macroglobulinemia — is a lymphoplasmacytic lymphoma secreting monoclonal IgM that causes hyperviscosity rather than lytic bone disease or hypercalcemia; the bone/calcium picture defeats it (buzzword-matching a monoclonal protein)
  • Smoldering multiple myeloma — the 30% clonal marrow plasma cells fall within the smoldering range, but smoldering myeloma by definition has no myeloma-defining event; the hypercalcemia here is a CRAB feature of end-organ damage, which makes this symptomatic myeloma (anchoring on the plasma cell percentage alone)
Question 8HematologyMedium
A 22-year-old woman with homozygous HbSS sickle cell disease presents to the ED with 9/10 diffuse bone pain in the back, arms, and legs that started 6 hours ago. She reports no fever, cough, or chest pain. Temperature is 37.1 C, BP 128/76 mmHg, HR 104/min, RR 18/min, SpO2 98% on room air. Exam shows tenderness over the long bones without swelling or erythema. Labs show Hgb 8.1 g/dL (baseline 8 g/dL), WBC 9.8, reticulocytes 9%. Which of the following is the most appropriate next step in management?
  • AIV fluids and IV opioid analgesia
  • BSimple packed red blood cell transfusion
  • CInitiate oral hydroxyurea therapy
  • DExchange transfusion
  • ESupplemental oxygen via nasal cannula
Reveal answer & full explanation
Correct answer: A — IV fluids and IV opioid analgesia
  • AIV fluids and IV opioid analgesia✓
  • BSimple packed red blood cell transfusion
  • CInitiate oral hydroxyurea therapy
  • DExchange transfusion
  • ESupplemental oxygen via nasal cannula

Why IV fluids and IV opioid analgesia is correct

  • This patient is in an uncomplicated vaso-occlusive crisis (VOC), the hallmark acute presentation of sickle cell disease
  • VOC is driven by HbS polymerization, RBC sickling, and microvascular occlusion producing ischemic bone pain
  • First-line acute management is prompt parenteral opioid analgesia within 30–60 minutes of arrival, titrated to pain control
  • IV hydration should target euvolemia (oral preferred; IV fluids only if the patient is volume-depleted or cannot take oral intake) — over-aggressive fluids worsen acute chest syndrome and pulmonary edema risk
  • Supplemental oxygen is given only for hypoxia; this patient's SpO2 is 98% on room air
  • Hemoglobin is at baseline (8.1 g/dL vs. baseline 8 g/dL), so transfusion is not indicated

Why the others are wrong

  • Exchange transfusion — reserved for severe complications such as acute chest syndrome, stroke, or multiorgan failure; not indicated for uncomplicated VOC
  • Initiate oral hydroxyurea therapy — hydroxyurea raises fetal hemoglobin and lowers the frequency of future crises, but its effect takes weeks to months; it is chronic outpatient prophylaxis that does nothing for the pain of an acute VOC, so it is not an ED intervention
  • Simple packed red blood cell transfusion — not routinely indicated for VOC because Hgb is at baseline; transfusion is used for symptomatic anemia, aplastic crisis, or acute chest syndrome
  • Supplemental oxygen via nasal cannula — oxygen is often assumed to reverse sickling, but in a patient who is not hypoxemic it neither shortens a vaso-occlusive crisis nor relieves pain; it is reserved for hypoxia, and this patient's SpO2 is 98% on room air while her 9/10 pain still needs prompt parenteral opioids

Additional high-yield points

  • Hydroxyurea is used for chronic prophylaxis of VOC, not for acute crisis management
Question 9HematologyMedium
A 72-year-old man presents with several months of fatigue and easy bruising. Complete blood count shows hemoglobin 9.8 g/dL, white blood cells 4,200/mm3, platelets 88,000/mm3, and mean corpuscular volume 104 fL. Bone marrow biopsy reveals neutrophils with hypolobated nuclei (pseudo-Pelger-Huet cells), hypogranular platelets, and 8% myeloblasts. Which of the following is the most likely diagnosis?
  • APrimary myelofibrosis
  • BAcute myeloid leukemia
  • CAplastic anemia
  • DMyelodysplastic syndrome
  • EFolate deficiency anemia
Reveal answer & full explanation
Correct answer: D — Myelodysplastic syndrome
  • APrimary myelofibrosis
  • BAcute myeloid leukemia
  • CAplastic anemia
  • DMyelodysplastic syndrome✓
  • EFolate deficiency anemia

Why Myelodysplastic syndrome is correct

  • Myelodysplastic syndrome is a clonal hematopoietic stem cell disorder defined by dysplastic maturation plus peripheral cytopenias, both present here.
  • Pseudo-Pelger-Huet neutrophils, hypogranular platelets, and macrocytosis (MCV 104 fL) are classic dysplastic findings.
  • 8% marrow blasts falls in the 5-9% range of MDS with excess blasts, which carries a higher risk of transformation to acute myeloid leukemia.

Why the others are wrong

  • Folate deficiency anemia - the macrocytosis is a buzzword trap, but folate deficiency causes megaloblastic change (hypersegmented neutrophils), not pseudo-Pelger-Huet dysplasia or marrow blasts.
  • Aplastic anemia - also produces pancytopenia (premature-closure trap), but the marrow is hypocellular without dysplasia or excess blasts; 8% blasts and dysplastic forms exclude it.
  • Acute myeloid leukemia - requires 20% or more blasts; 8% does not meet the threshold (right-disease-spectrum, wrong-cutoff).
  • Primary myelofibrosis - another clonal myeloid neoplasm of older adults that causes anemia (look-alike trap), but its hallmarks are marrow fibrosis with atypical megakaryocytes, often a dry tap, a leukoerythroblastic smear with teardrop cells, and splenomegaly, not pseudo-Pelger-Huet neutrophils and hypogranular platelets.
Question 10HematologyMedium
A 55-year-old man with multiple myeloma on lenalidomide maintenance develops acute bilateral lower extremity deep vein thrombosis. He has chronic kidney disease stage 3 (eGFR 42 mL/min/1.73 m2). Which of the following is the most appropriate anticoagulation?
  • AWarfarin
  • BLow-molecular-weight heparin (LMWH) (enoxaparin)
  • CFondaparinux
  • DApixaban
  • EDabigatran
Reveal answer & full explanation
Correct answer: D — Apixaban
  • AWarfarin
  • BLow-molecular-weight heparin (LMWH) (enoxaparin)
  • CFondaparinux
  • DApixaban✓
  • EDabigatran

Why Apixaban is correct

  • For cancer-associated venous thromboembolism, direct oral anticoagulants (apixaban, rivaroxaban) are preferred over low-molecular-weight heparin for most patients per CHEST 2021 and ASH 2021 guidance (ASCO 2023 lists LMWH and these agents as equally acceptable), with equal or better efficacy and oral dosing.
  • Apixaban is the least renally cleared direct oral anticoagulant and needs no renal dose adjustment for VTE; the pivotal VTE trial (AMPLIFY) excluded creatinine clearance below 25 mL/min, so data are limited below that, and an eGFR of 42 is within the studied range.
  • Lenalidomide markedly raises venous thromboembolism risk in myeloma, so full therapeutic anticoagulation is indicated.

Why the others are wrong

  • Fondaparinux — a once-daily subcutaneous factor Xa inhibitor that is an acceptable alternative to LMWH for initial VTE treatment, but it is cleared entirely by the kidney (caution at creatinine clearance 30-50 mL/min, contraindicated below 30), commits the patient to indefinite injections, and is not a guideline-preferred agent for cancer-associated venous thromboembolism (right-target, wrong-agent trap).
  • Low-molecular-weight heparin (LMWH) (enoxaparin) — the former standard, still an acceptable guideline option (enoxaparin needs no dose change at creatinine clearance of 30 mL/min or higher), but oral factor Xa inhibitors are now favored for most patients, with LMWH preferred mainly for luminal GI or GU cancers with high bleeding risk; this patient has neither, so daily injections offer no advantage over apixaban (right-idea, outdated-standard trap).
  • Warfarin — variable INR control and chemotherapy drug interactions make it the least-preferred agent in cancer-associated venous thromboembolism (right-class, wrong-agent trap).
  • Dabigatran — a direct oral anticoagulant, so it seems interchangeable with apixaban, but it is about 80% renally cleared, requires 5-10 days of parenteral lead-in for VTE, and lacks the cancer-associated venous thromboembolism trial data behind apixaban, rivaroxaban, and edoxaban, so it is not a guideline-preferred agent here (same-class, wrong-agent trap).

That's 10 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → See today's free PANCE question →

Hematology PANCE practice: FAQ

Are these Hematology PANCE practice questions free?

Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.

How much of the PANCE is Hematology?

Hematology makes up 5% of the PANCE content blueprint. FirstPassPA's timed PANCE exams are dealt to the same weights, so a practice exam carries the same share of Hematology questions.

How should I use these questions?

Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Hematology questions in the app, or take a full timed PANCE practice exam dealt to the blueprint weights.

Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.